Osteosarcoma is a primary malignant bone
tumor that has a poor prognosis due to local recurrence,
metastasis, and
chemotherapy resistance. Therefore, there is an urgent need to develop novel potential therapeutic targets for
osteosarcoma. Enhancer of zeste homologue 2 (EZH2) is a member of the polycomb group of
proteins, which has important functions in epigenetic silencing and cell cycle regulation. Overexpression of EZH2 has been found in several
malignancies, however, its expression and the role of EZH2 in
osteosarcoma is largely unknown. In this study, we examined EZH2 expression by immunohistochemistry in a large series of
osteosarcoma tissues in association with
tumor characteristics and patient outcomes. EZH2 expression was also analyzed in a microarray dataset of
osteosarcoma. Results showed that higher expression of EZH2 was significantly associated with more aggressive
tumor behavior and poor patient outcomes of
osteosarcoma. We subsequently investigated the functional and therapeutic relevance of EZH2 as a target in
osteosarcoma. Immunohistochemical analysis indicated that EZH2 expression was significantly associated with more aggressive
tumor behavior and poorer patient outcomes of
osteosarcoma. EZH2 silencing by
siRNA inhibited
osteosarcoma cell growth, proliferation, migration, and invasion. Moreover, suppression of EZH2 attenuated cancer stem cell functions. Similar results were observed in
osteosarcoma cells treated with EZH2 specific inhibitor
3-deazaneplanocin A (
DZNep), which exhausted cellular levels of EZH2. These results suggest that EZH2 is critical for the growth and
metastasis of
osteosarcoma, and an epigenetic
therapy that pharmacologically targets EZH2 via specific inhibitors may constitute a novel approach to the treatment of
osteosarcoma.